CClinicalTrials.gg
CompletedNCT04094220Updated Dec 29, 2023

LLIF Plus Posterior Decompression for Severe Lumbar Spinal Stenosis

An interventional study of Lateral lumbar interbody fusion in Lumbar Spine Degeneration and Lumbar Spinal Stenosis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Completed at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-29.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

Lateral lumbar interbody fusion (LLIF), as a minimally invasive technique, is an indirect decompression technique, and its decompression effect is not as thorough as traditional posterior decompression surgery. For certain patients with severe lumbar stenosis, additional posterior decompression is required. However, whether additional posterior decompression is necessary for these patients is unknown. Radiographic predictors of failed indirect decompression via LLIF is unknown. In current randomized, controlled trial , the investigators compare the clinical outcomes of patients with severe lumbar stenosis who received LLIF plus posterior decompression and those without posterior decompression.

Read the detailed description

The current randomized controlled trial consists of two groups. Patients included in the study are with Schizas's stenosis grades C. Patients in one group received transpsoas lateral lumbar interbody fusion. Patients in the other group received transpsoas lateral lumbar interbody fusion plus posterior decompression. Patients will be followed for one year. Clinical outcomes of the two groups will be compared. And radiographic predictors of failed indirect decompression via LLIF will be analyzed.

02

Conditions studied

  • Lumbar Spine Degeneration
  • Lumbar Spinal Stenosis

Keywords

  • indirect decompression
  • lateral interbody fusion
  • lumbar
  • direct decompression
03

In context

Spinal Stenosis

459 studies on the registry are indexed under Spinal Stenosis; 103 are open to participants now.

This study's enrollment of 72 is close to the median of 80 across 283 interventional studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,058 studies on the registry; 511 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female patients who are 50 - 80 years of age.
  • Patients who present with symptomatic Grade I or II degenerative spondylolisthesis at one or two contiguous lumbar levels between L1 and L5 and who are surgical candidates for interbody lumbar fusion surgery; symptoms should include radiculopathy and/or neurogenic claudication with or without back pain.
  • Patients who have been unresponsive to at least 6 months of conservative treatments or who exhibit progressive neurological symptoms in the face of conservative treatment.
  • Patients who understand the conditions of enrollment and are willing to sign an informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with lumbar pathologies requiring treatment at more than two levels.
  • Patients who have had previous lumbar fusion surgery.
  • Patients with congenital lumbar stenosis.
  • Patients with radiographic confirmation of Grade IV facet joint disease or degeneration.
  • Patients with noncontained or extruded herniated nucleus pulposus.
  • Patients with active local or systemic infection.
  • Patients with rheumatoid arthritis or other autoimmune disease.
  • Patients who cannot undergo magnetic resonance imaging (MRI).
  • Patients who are mentally incompetent.
  • Patients with BMI over 30kg/m2 or less than 18 kg/m2.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Lateral lumbar interbody fusion

    Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.

    Procedure: Lateral lumbar interbody fusion

  • Experimental
    Lateral lumbar interbody fusion plus posterior decompression

    Patients in this group received lateral lumbar interbody fusion plus posterior decompression.

    Procedure: Lateral lumbar interbody fusion

Interventions

  • ProcedureLateral lumbar interbody fusion

    LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.

06

What researchers measure

Primary outcomes

  1. Oswestry Disability Index (ODI)

    The ODI is an extremely important tool that researchers and disability evaluators use to measure a patient's permanent functional disability

    Time frame: Preoperative, 3-month, 12-month,24-month after surgery

Secondary outcomes

  1. Visual Analogue Scale (VAS)

    The VAS is a self-report measure of the intensity of pain (score range 0 - 10 ). A higher score indicates greater pain intensity.

    Time frame: Preoperative, 3-month, 12-month,24-month after surgery

  2. Zurich Claudication Questionnaire(ZCQ)

    The ZCQ is a disease-specific self-report outcome instrument commonly used in trials to measure treatment outcomes in patients with lumbar spinal stenosis.The result is expressed as a percentage of the maximum possible score (22.22% - 100%). The score increases with worsening disability.The The ZCQ consists of three subscales: symptom severity scale, physical function scale and patient's satisfaction with treatment scale.

    Time frame: Preoperative, 3-month, 12-month,24-month after surgery

Other outcomes

  1. Axial central canal area

    The area of the spinal central canal with the most stenosis at the level of the intervertebral disc on MRI.

    Time frame: Preoperative,postoperative,12-month,24-month after surgery

  2. Midsagittal canal diameter

    The canal diameter at the midsagittal slice on MRI.

    Time frame: Preoperative,postoperative,12-month,24-month after surgery

  3. anterior and posterior disc height

    The disc height at the anterior and posterior rim of the intervertebral disc on X-ray.

    Time frame: Preoperative,postoperative, 6-month,12-month,24-month after surgery

  4. The height of the bilateral intervertebral foramen

    The distance of minimum diameter between adjacent pedicles on CT.

    Time frame: Preoperative,postoperative, 6-month,12-month,24-month after surgery

  5. Disc angle

    The angles of the lines parallel to the upper and lower endplates in the intervertebral space.

    Time frame: Preoperative,postoperative, 6-month,12-month,24-month after surgery

07

Study locations

1 site
  • The Second Affiliated Hospital of Medical College Zhejiang University
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04094220
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Responsible party
Sponsor
First posted
Sep 18, 2019
Start date
Aug 1, 2019
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Last update
Dec 29, 2023

Study contacts

Fangcai Li, MD
principal investigator · The Second Affiliated Hospital of Medical College Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion